相关实验视频
Updated: Sep 19, 2025

08:10
The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
11.3K
在一个连续的两步过程中,轻松地将多巴胺生物氧化为6-氧多巴胺-昆:对帕金森病的影响
Xiang-Rong Jiang1, Bao Ting Zhu1,2
1Shenzhen Key Laboratory of Steroid Drug Discovery and Development, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Chemical research in toxicology
|June 5, 2025
概括
这项研究表明,多巴胺可以形成6-氧多巴胺 (6-OHDA),这是帕金森氏症.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 毒理学 毒理学 毒理学
背景情况:
- 6-氧多巴胺 (6-OHDA) 是一种多巴胺衍生物,用于诱导动物模型中的帕金森症症状.
- 目前,6-OHDA被广泛认为是一种合成神经毒剂,因为其内源存在或形成的证据有限.
- 在没有明确的生物形成途径的情况下,6-OHDA在帕金森病病原发生中的潜在作用仍然是推测性的.
研究的目的:
- 在生理学上相关的条件下调查6-OHDA形成的潜力.
- 阐明影响多巴胺产生6-OHDA的化学机制和生物因素.
- 提供支持或反驳6-OHDA作为帕金森病内在病因因素的假设的证据.
主要方法:
- 使用芬顿反应系统与Fe2+,甲酸和EDTA在酸缓冲区 (pH7.4) 中进行反应.
- 分析了多巴胺对多巴胺o (DAQ) 的序列氧化,随后对6-OHDAp.
- 研究过渡金属离子,基,过氧化,催化酶,谷和氨酸的作用.
主要成果:
- 多巴胺在芬顿反应系统中很容易被氧化为6-OHDA p-.
- 氧化过程通过涉及DAQ形成的两步过程发生,由Fe2+/3+和Mn2+/3+促进.
- catalase抑制了形成,而谷氨和囊通过形成结合物提供了保护.
结论:
- 6-氧多巴胺 (6-OHDA) 可以在模仿生理环境的条件下从多巴胺形成.
- 这一发现支持了长期以来的假设,即6-OHDA可能是帕金森病病因的内在因素.
- 这项研究为内源性6-OHDA生产提供了潜在的生化途径,与神经退行性疾病相关.
相关概念视频
Oxidation of Phenols to Quinones
3.5K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
3.5K
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Drug Metabolism: Phase I Reactions
3.8K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.8K
Phase I Oxidative Reactions: Overview
391
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
391

